These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9764547)

  • 1. Risk assessment and risk-based therapy in febrile neutropenic patients.
    Rolston KV
    Eur J Clin Microbiol Infect Dis; 1998 Jul; 17(7):461-3. PubMed ID: 9764547
    [No Abstract]   [Full Text] [Related]  

  • 2. Expanding the options for risk-based therapy in febrile neutropenia.
    Rolston KV
    Diagn Microbiol Infect Dis; 1998 Jun; 31(2):411-6. PubMed ID: 9635917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of febrile neutropenia].
    Urabe A
    Rinsho Ketsueki; 2009 Feb; 50(2):69-72. PubMed ID: 19265296
    [No Abstract]   [Full Text] [Related]  

  • 4. Important aspects of cost-effectiveness analysis in febrile neutropenia.
    Karthaus M; Boehme A; Ganser A; Juergens H
    Infection; 1999; 27(6):372-5. PubMed ID: 10624602
    [No Abstract]   [Full Text] [Related]  

  • 5. [Problems and proposals for revision of the Japanese guideline for febrile neutropenia].
    Yoshida M
    Rinsho Ketsueki; 2011 Apr; 52(4):182-9. PubMed ID: 21566403
    [No Abstract]   [Full Text] [Related]  

  • 6. Question 2: Unexpected neutropenia in a febrile, but immunocompetent, child.
    Knight K
    Arch Dis Child; 2015 Nov; 100(11):1093-5. PubMed ID: 26483439
    [No Abstract]   [Full Text] [Related]  

  • 7. Proceedings of the 4th International Symposium on Febrile Neutropenia. December 15-17, 1999.
    Int J Antimicrob Agents; 2000 Oct; 16(2):83-187. PubMed ID: 11203263
    [No Abstract]   [Full Text] [Related]  

  • 8. The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies.
    El-Maghraby SM; Moneer MM; Ismail MM; Shalaby LM; El-Mahallawy HA
    J Pediatr Hematol Oncol; 2007 Mar; 29(3):131-6. PubMed ID: 17356388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy.
    Erjavec Z; de Vries-Hospers HG; Laseur M; Halie RM; Daenen S
    J Antimicrob Chemother; 2000 Jun; 45(6):843-9. PubMed ID: 10837439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Microbiological isolates in patients with febrile neutropenia and hematological neoplasias].
    Figuera Esparza M; Carballo M; Silva M; Figueredo A; Avilán J
    Rev Esp Quimioter; 2006 Sep; 19(3):247-51. PubMed ID: 17099792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of C-reactive protein during febrile neutropenia in pediatric malignancies.
    Avabratha KS; Rau AT; Venkataravanamma P; Rau A
    Indian Pediatr; 2009 Sep; 46(9):797-9. PubMed ID: 19430077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.
    Bow EJ; Rotstein C; Noskin GA; Laverdiere M; Schwarer AP; Segal BH; Seymour JF; Szer J; Sanche S
    Clin Infect Dis; 2006 Aug; 43(4):447-59. PubMed ID: 16838234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report on outpatient management of patients with neutropenic fever in a tertiary hospital.
    Dzienis MR; Shahidzadeh Mahani A
    Intern Med J; 2017 Jan; 47(1):122-123. PubMed ID: 28076904
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibiotic management of febrile neutropenia: current developments and future directions.
    Mebis J; Goossens H; Berneman ZN
    J Chemother; 2010 Feb; 22(1):5-12. PubMed ID: 20227985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The spectrum of bacterial infections in febrile neutropenic patients: effect on empiric antibiotic therapy.
    Burney IA; Farooqui BJ; Siddiqui T; Khurshid M
    J Pak Med Assoc; 1998 Dec; 48(12):364-7. PubMed ID: 10531769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit.
    Cumpston A; Craig M; Hamadani M; Abraham J; Hobbs GR; Sarwari AR
    Transpl Infect Dis; 2013 Apr; 15(2):142-9. PubMed ID: 23279656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
    Flowers CR; Seidenfeld J; Bow EJ; Karten C; Gleason C; Hawley DK; Kuderer NM; Langston AA; Marr KA; Rolston KV; Ramsey SD
    J Clin Oncol; 2013 Feb; 31(6):794-810. PubMed ID: 23319691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Febrile neutropenia: past, present and future.
    Neth O; Klein N
    Adv Exp Med Biol; 2004; 549():119-24. PubMed ID: 15250524
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients.
    Malik IA; Abbas Z; Karim M
    Lancet; 1992 May; 339(8801):1092-6. PubMed ID: 1349112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Admission and care of the febrile neutropenic patient in a community hospital setting.
    Ford MS; Helsley M
    J Support Oncol; 2005; 3(6 Suppl 4):22-3. PubMed ID: 16355555
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.